Elias Mouchlianitis1, Michael A P Bloomfield2, Vincent Law3, Katherine Beck4, Sudhakar Selvaraj5, Naresh Rasquinha6, Adam Waldman7, Federico E Turkheimer4, Alice Egerton4, James Stone8, Oliver D Howes8. 1. Medical Research Council Clinical Sciences Centre, Psychiatric Imaging Group, Hammersmith Hospital, London, UK; Institute of Psychiatry Psychology and Neuroscience, Department of Psychosis Studies, King's College London, UK; elias.mouchlianitis@kcl.ac.uk. 2. Medical Research Council Clinical Sciences Centre, Psychiatric Imaging Group, Hammersmith Hospital, London, UK; University College London, Division of Psychiatry, London, UK; 3. Medical Research Council Clinical Sciences Centre, Psychiatric Imaging Group, Hammersmith Hospital, London, UK; 4. Institute of Psychiatry Psychology and Neuroscience, Department of Psychosis Studies, King's College London, UK; 5. Department of Psychiatry and Behavioral Sciences, University of Texas, Houston, TX; 6. Partnerships in Care, Mental Health Division, London, UK; 7. Division of Brain Sciences, Imperial College London, Hammersmith Hospital, London, UK. 8. Medical Research Council Clinical Sciences Centre, Psychiatric Imaging Group, Hammersmith Hospital, London, UK; Institute of Psychiatry Psychology and Neuroscience, Department of Psychosis Studies, King's College London, UK;
Abstract
INTRODUCTION: Resistance to antipsychotic treatment is a significant clinical problem in patients with schizophrenia with approximately 1 in 3 showing limited or no response to repeated treatments with antipsychotic medication. The neurobiological basis for treatment resistance is unknown but recent evidence implicates glutamatergic function in the anterior cingulate cortex. We examined glutamate levels of chronically ill treatment-resistant patients directly compared to treatment-responsive patients. METHODS: We acquired proton magnetic resonance spectroscopy (1H-MRS) at 3 Tesla from 21 treatment-resistant and 20 treatment-responsive patients. All participants had a DSM-IV diagnosis of schizophrenia. Treatment-resistant patients were classified using the modified Kane criteria. The groups were matched for age, sex, smoking status, and illness duration. RESULTS: Glutamate to creatine ratio levels were higher in treatment-resistant patients (Mean [SD] = 1.57 [0.24]) than in treatment-responsive patients (Mean[SD] = 1.38 [0.23]), (T[35] = 2.34, P = .025, 2-tailed), with a large effect size of d = 0.76. A model assuming 2 populations showed a 25% improvement in the fit of the Akaike weights (0.55) over a model assuming 1 population (0.44), producing group values almost identical to actual group means. DISCUSSION: Increased anterior cingulate glutamate level is associated with treatment-resistant schizophrenia. This appears to be a stable neurobiological trait of treatment-resistant patients. We discuss possible explanations for glutamatergic dysfunction playing a significant role in resistance to conventional antipsychotic treatments, which are all dopamine-2 receptor blockers. Our findings suggest that glutamatergic treatments may be particularly effective in resistant patients and that 1H-MRS glutamate indices can potentially have clinical use.
INTRODUCTION: Resistance to antipsychotic treatment is a significant clinical problem in patients with schizophrenia with approximately 1 in 3 showing limited or no response to repeated treatments with antipsychotic medication. The neurobiological basis for treatment resistance is unknown but recent evidence implicates glutamatergic function in the anterior cingulate cortex. We examined glutamate levels of chronically ill treatment-resistant patients directly compared to treatment-responsive patients. METHODS: We acquired proton magnetic resonance spectroscopy (1H-MRS) at 3 Tesla from 21 treatment-resistant and 20 treatment-responsive patients. All participants had a DSM-IV diagnosis of schizophrenia. Treatment-resistant patients were classified using the modified Kane criteria. The groups were matched for age, sex, smoking status, and illness duration. RESULTS: Glutamate to creatine ratio levels were higher in treatment-resistant patients (Mean [SD] = 1.57 [0.24]) than in treatment-responsive patients (Mean[SD] = 1.38 [0.23]), (T[35] = 2.34, P = .025, 2-tailed), with a large effect size of d = 0.76. A model assuming 2 populations showed a 25% improvement in the fit of the Akaike weights (0.55) over a model assuming 1 population (0.44), producing group values almost identical to actual group means. DISCUSSION: Increased anterior cingulate glutamate level is associated with treatment-resistant schizophrenia. This appears to be a stable neurobiological trait of treatment-resistant patients. We discuss possible explanations for glutamatergic dysfunction playing a significant role in resistance to conventional antipsychotic treatments, which are all dopamine-2 receptor blockers. Our findings suggest that glutamatergic treatments may be particularly effective in resistant patients and that 1H-MRS glutamate indices can potentially have clinical use.
Authors: Lawrence S Kegeles; Xiangling Mao; Arielle D Stanford; Ragy Girgis; Najate Ojeil; Xiaoyan Xu; Roberto Gil; Mark Slifstein; Anissa Abi-Dargham; Sarah H Lisanby; Dikoma C Shungu Journal: Arch Gen Psychiatry Date: 2012-01-02
Authors: Alice Egerton; Stefan Brugger; Marie Raffin; Gareth J Barker; David J Lythgoe; Philip K McGuire; James M Stone Journal: Neuropsychopharmacology Date: 2012-07-04 Impact factor: 7.853
Authors: Jean Théberge; Yousef Al-Semaan; Peter C Williamson; Ravi S Menon; Richard W J Neufeld; Nagalingam Rajakumar; Betsy Schaefer; Maria Densmore; Dick J Drost Journal: Am J Psychiatry Date: 2003-12 Impact factor: 18.112
Authors: James M Stone; Fiona Pepper; Johnson Fam; Hannah Furby; Emer Hughes; Celia Morgan; Oliver D Howes Journal: Psychopharmacology (Berl) Date: 2013-11-22 Impact factor: 4.530
Authors: Daniel C Javitt; Cameron S Carter; John H Krystal; Joshua T Kantrowitz; Ragy R Girgis; Lawrence S Kegeles; John D Ragland; Richard J Maddock; Tyler A Lesh; Costin Tanase; Philip R Corlett; Douglas L Rothman; Graeme Mason; Maolin Qiu; James Robinson; William Z Potter; Marlene Carlson; Melanie M Wall; Tse-Hwei Choo; Jack Grinband; Jeffrey A Lieberman Journal: JAMA Psychiatry Date: 2018-01-01 Impact factor: 21.596
Authors: Henry Sershen; Audrey Hashim; David S Dunlop; Raymond F Suckow; Tom B Cooper; Daniel C Javitt Journal: Neurochem Res Date: 2016-02-08 Impact factor: 3.996
Authors: S Andrea Wijtenburg; Susan N Wright; Stephanie A Korenic; Frank E Gaston; Nkemdilim Ndubuizu; Joshua Chiappelli; Robert P McMahon; Hongji Chen; Anya Savransky; Xiaoming Du; Danny J J Wang; Peter Kochunov; L Elliot Hong; Laura M Rowland Journal: Neuropsychopharmacology Date: 2016-08-26 Impact factor: 7.853
Authors: Meredith A Reid; Nouha Salibi; David M White; Timothy J Gawne; Thomas S Denney; Adrienne C Lahti Journal: Schizophr Bull Date: 2019-01-01 Impact factor: 9.306